A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

NCT04700449 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Ulcerative Colitis

Interventions

DRUG: Double-Blind 0.2mg CBP-307
DRUG: Double-Blind Placebo
DRUG: Open-label CBP-307
DRUG: Double-Blind 0.1mg CBP-307

Sponsor

Connect Biopharm LLC